.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Fish and Richardson
US Department of Justice
Mallinckrodt
Teva
Express Scripts
Harvard Business School
Accenture
US Army
Colorcon

Generated: September 19, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins
Abstract: An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin.
Inventor(s): Cheong; Kwang Ho (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Lin; Powei (Hwaseong-si, KR), Lee; Saet Byoul (Seoul, KR), Hwang; Jae Woong (Seoul, KR)
Assignee: SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR)
Application Number:14/625,296
Patent Claims:1. An anti-EGFR/anti-HER2 bispecific antibody comprising: an anti-EGFR DARPin, and an anti-HER2 antibody, wherein the anti-HER2 antibody is an IgG antibody or an scFv-Fc antibody, or a combination thereof.

2. The bispecific antibody of claim 1, wherein the anti-EGFR DARPin comprises at least one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, and wherein at least one EGFR DARPin is, optionally, repeated 2 to 10 times.

3. The bispecific antibody of claim 1, wherein the anti-HER2 antibody is (1) trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 6; or (2) an scFv-Fc antibody comprising an antigen-binding fragment of trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 6.

4. A pharmaceutical composition comprising the anti-EGFR/anti-HER2 bispecific antibody of claim 1.

5. A method of treating a cancer in a subject, comprising administering the anti-EGFR/anti-HER2 bispecific antibody of claim 1 to the subject, wherein the cancer is characterized by the expression of EGFR and HER2.

6. A method of preparing an anti-EGFR/anti-HER2 bispecific antibody of claim 1, comprising linking an anti-EGFR DARPin, and an anti-HER2 antibody, wherein the anti-HER2 antibody is an IgG antibody, a scFv-Fc antibody, or a combination thereof.

7. The method of claim 6, wherein the anti-EGFR DARPin comprises at least one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, and wherein at least one EGFR DARPin is, optionally, repeated 2 to 10 times.

8. The method of claim 6, wherein the anti-HER2 antibody is (1) trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6; or (2) a scFv-Fc antibody comprising an antigen-binding fragment of trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 6.

9. A method of enhancing the efficacy of an anti-HER2 antibody, comprising binding an anti-EGFR DARPin to an anti-HER2 antibody, wherein the anti-HER2 antibody is an IgG antibody, an scFv-Fc antibody, or a combination thereof.

10. The method of claim 9, wherein the anti-EGFR DARPin comprises at least one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and wherein at least one DARPin is, optionally, repeated 2 to 10 times.

11. The method of claim 9, wherein the anti-HER2 antibody is (1) trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 6; or (2) a scFv-Fc antibody comprising an antigen-binding fragment of trastuzumab, pertuzumab, trastuzumab emtansine, or an anti-HER2 IgG antibody comprising a heavy chain variable region comprising SEQ ID NO: 5 and a light chain variable region comprising SEQ ID NO: 6.

12. A nucleic acid encoding the bispecific antibody of claim 1, optionally in a vector.

13. A cell comprising the nucleic acid of claim 12.

14. A method of preparing a bispecific antibody of claim 1 comprising expressing a nucleic acid encoding the bispecific antibody in a cell.

15. The method of claim 5, wherein the subject is a cancer patient having resistance against an EGFR antagonist.

16. The method of claim 5, wherein the subject is a cancer patient having resistance against an anti-HER2 antibody.

17. The method of claim 5, wherein the subject is a cancer patient having resistance against an EGFR antagonist and an anti-HER2 antibody.

18. The antibody of claim 1, wherein treatment of a gastric cancer cell with the antibody causes internalization of HER2 and EGFR.

19. The method of claim 5, wherein the antibody causes internalization of HER2 and EGFR.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
South Korea10-2014-0018649Feb 18, 2014

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Genentech
HERCEPTIN
trastuzumab
VIAL; INTRAVENOUS1037920011998-09-25► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) Cheong; Kwang Ho (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Lin; Powei (Hwaseong-si, KR), Lee; Saet Byoul (Seoul, KR), Hwang; Jae Woong (Seoul, KR) ► SubscribeRXOrphansearch
Genentech
PERJETA
pertuzumab
VIAL; SINGLE-USE1254090012012-06-08► Subscribe SAMSUNG ELECTRONICS CO., LTD. (Suwon-Si, KR) Cheong; Kwang Ho (Seoul, KR), Lee; Seung Hyun (Suwon-si, KR), Lin; Powei (Hwaseong-si, KR), Lee; Saet Byoul (Seoul, KR), Hwang; Jae Woong (Seoul, KR) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
South Korea20150097304Aug 26, 2015
United States of America2015232573Aug 20, 2015
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Farmers Insurance
Fuji
Baxter
Accenture
Mallinckrodt
Cantor Fitzgerald
McKesson
Chubb
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot